CytomX Therapeutics, Inc. — Director's Dealing 2021

Jun 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CytomX Therapeutics, Inc. (CTMX)
CIK: 0001501989
Period of Report: 2021-06-16

Reporting Person: Jones Elaine V (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-16	Stock Option (Right to Buy)	$7.13	A	20000	Acquired	2031-06-15	Common Stock (20000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.